Proactive Investors - Run By Investors For Investors

Redx Pharma confirms start of phase I study of lead drug RXC004

Redx Pharma Plc's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott following the release of their interims to the end of March 2019.

Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year, with the full read-out expected in early 2020.

Redx has also secured short-term funding with a loan of up to £2.5mln and is in talks to find a longer-term financing solution.

 
Meet Cardinal Resources Ltd, Legend Mining Ltd, Danakali Ltd, Predictive Discovery Ltd and Alliance Resources Ltd at our event, Melbourne , 16 July 2019. Register here »
View full REDX profile View Profile

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use